AB0908 ARE CHRONIC PAIN SYNDROMES BEHIND STATIN-ASSOCIATED MUSCLE PAIN?. (June 2019)

• Record Type: Journal Article
• Authors: Yavne, Yarden; Sheinin, Rivka; Nogueira, Rita; Bragazzi, Nicola Luigi; Tiosano, Shmuel; Watad, Abdulla; Sharif, Kassem; Amital, Daniela; Cohen, Hofit; Amital, Howard
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1920
• Page End: 1921
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.3349
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Statin myalgia, defined as muscle pain or weakness without elevation of CPK levels, is a common complaint among statin users. Chronic pain syndromes affect a high percentage of the population 1, therefore it is likely that such syndromes may confound reports of statin myalgia. Objectives: The objective of this study was to compare the occurence of chronic pain between patients taking statins who later developed myalgia with those who did not. Methods: This study included 112 statin-treated patients at the Lipid Center in Tel Hashomer - 56 of whom were diagnosed with Statin Asocciated Muscle Symptoms [SAMS] and 56 patients who were not. Questionnaires were used to assess diagnoses of fibromyalgia, pain intensity, functional impairment, anxiety and depression in the study population. Results: Patients with statin myalgia were more likely to fulfill the diagnostic criteria for fibromyalgia than patients without stating myalgia (11 vs. 0, respectively). Patients in the SAMS group also exhibited higher levels of anxiety and depression in comparison with the control group. Female sex, scoring in Brief Pain Inventory pain intensity, and a Hamilton level indicative of an anxiety disorder were found to be significant predictors for fibromyalgia in patients suffering from stating myalgia. Conclusion: A significant percentage of patients who were thought to suffer from statin myalgia fulfill the criteria for fibromyalgia, depression or anxiety. Detection of these patients and treatment of their priamry pain or psychiatric illness may prevent cessation of effective statin therapy. Reference: [1] Cho L, Rocco M, Colquhoun D, et al. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovasc Drugs Ther2016;30(3):297–304. Disclosure of Interests: Yarden Yavne: None declared, Rivka Sheinin: None declared, Rita Nogueira: None declared, Nicola Luigi Bragazzi: None declared, Shmuel Tiosano: None declared, Abdulla Watad: None declared, Kassem Sharif: None declared, Daniela Amital: None declared, Hofit Cohen: None declared, Howard Amital Grant/research support from: Pfizer, AbbVie, Janssen, Grant/research support from: Pfizer, AbbVie, Janssen, Consultant for: Pfizer, Merck Sharp & Dohme, Consultant for: Pfizer, Merck Sharp & Dohme, Speakers bureau: Pfizer, Merck Sharp & Dohme, Janssen, Sanofi, Bristol-Myers Squibb, Abbvie, Neopharm, Speakers bureau: Pfizer, Merck Sharp & Dohme, Janssen, Sanofi, Bristol-Myers Squibb, Abbvie, Neopharm